GleamWall
中文EN

SCYX SCYNEXIS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1178253 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY544.0%
TTM net income YoY60.1%
TTM EPS YoY127.8%
Revenue 3-yr CAGR-48.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-126.9%
Net margin-53.5%
FCF margin—
EBITDA margin—

Returns

ROE-21.2%
ROA-17.0%
ROIC (approx.)-52.4%
Asset turnover0.32x

Leverage & solvency

Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.19x
Accruals ratio3.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$235,000$0$18.65M$334,000$1.36M$257,000$977,000
R&D expense$6.20M$3.89M$12.35M$4.54M$5.45M$7.14M$5.14M$4.31M
SG&A expense$3.56M$4.12M$4.59M$3.58M$3.29M$3.78M$3.73M$4.72M
Operating income-$9.76M-$7.78M-$16.94M$10.52M-$8.40M-$9.56M-$8.61M-$8.05M
Interest expense$0$0$0$0$0$0$173,000$211,000
Pretax income———$12.26M-$8.59M-$6.88M-$5.39M-$4.41M
Income tax———$0$0$0$0$23,000
Net income-$8.46M$7.40M-$21.30M$12.26M-$8.59M-$6.88M-$5.39M-$4.43M
EBITDA———————-$8.05M
EPS (basic)-0.710.63-0.42—-1.38-1.11-0.11—
EPS (diluted)-0.710.63-0.42—-1.38-1.11-0.11—
Weighted avg. shares (diluted)11.84M11.82M50.96M—6.24M6.22M49.44M—
Balance sheet
Cash & equivalents$8.23M$10.49M$36.67M$21.26M$14.99M$11.26M$7.49M$16.59M
Short-term investments$38.94M$43.60M$22.59M$18.77M$23.13M$33.77M$33.66M$43.25M
Current assets$50.36M$56.24M$62.69M$40.37M$48.69M$56.50M$52.22M$72.18M
Total assets$67.95M$74.97M$77.63M$59.03M$51.07M$60.69M$67.92M$90.64M
Current liabilities$6.65M$5.83M$15.90M$5.73M$8.47M$10.86M$8.96M$24.10M
Total liabilities$8.90M$8.04M$36.32M$9.65M$14.64M$16.23M$17.38M$35.57M
Shareholders' equity$59.05M$66.93M$41.31M$49.38M$36.43M$44.47M$50.53M$55.08M
Shares outstanding9.95M9.95M62.05M5.44M41.96M39.17M39.02M37.97M
Cash flow statement
Operating cash flow-$7.47M-$14.88M-$8.10M$18.40M-$8.72M-$7.50M-$7.46M-$9.91M
Investing cash flow$5.80M-$24.76M-$525,000-$11.82M$12.42M$11.27M$12.44M-$2.62M
Financing cash flow-$593,000$13.46M$24.04M-$115,000$29,000$0-$14.08M-$155,000
Depreciation & amortization———————$0
Stock-based compensation$562,000$568,000$580,000$687,000$526,000$820,000$819,000$981,000

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.